GLP-1 Market
LLY $1351.12 ▼ -2.3% NVO $38.87 ▼ -1.4% PFE $27.54 ▼ -1.9% VKTX $25.84 ▼ -1.3% KLRA $11.58 ▼ -1.8% GPCR $17.12 ▼ -1.4% RHHBY $58.99 ▼ -0.9%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

MenACWY vaccine

Company
Swiss Federal Institute of Technology
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 20, 2026

Trial details
  • Completed NCT NCT00471081

    Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

    Not yet reported GlaxoSmithKline 385 participants Est. completion 2008-11-26 19 sites
    Other conditions: Infections, Meningococcal
    View official trial listing →
  • Completed NCT NCT00474487

    A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults

    Not yet reported Novartis Vaccines 2831 participants Est. completion 2008-02 2 sites Stand-alone
    Other conditions: Meningococcal Meningitis, Meningococcal Infections
    View official trial listing →
  • Completed NCT NCT00601731

    Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

    Not yet reported Novartis Vaccines 382 participants Est. completion 2010-09 3 sites Stand-alone
    Other conditions: Meningococcal Disease
    View official trial listing →
  • Completed NCT NCT01018732

    A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY

    Not yet reported Novartis Vaccines 155 participants Est. completion 2010-07 3 sites
    Other conditions: Meningococcal Disease, Meningococcal Meningitis
    View official trial listing →
  • Completed NCT NCT01192997

    Comparison of Two Meningococcal ACWY Conjugate Vaccines

    Not yet reported, Not yet reported Public Health England 91 participants Est. completion 2014-03 3 sites
    Other conditions: Meningococcal Meningitis
    View official trial listing →
  • Completed NCT NCT01992536

    Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

    Not yet reported Novartis Vaccines 194 participants Est. completion 2015-04 13 sites Stand-alone
    Other conditions: Meningococcal Disease
    View official trial listing →
  • Completed NCT NCT02140762

    Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

    Not yet reported Novartis Vaccines 305 participants Est. completion 2015-02 8 sites
    Other conditions: Meningococcal Disease
    View official trial listing →
  • Completed NCT NCT02285777

    Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

    Not yet reported GlaxoSmithKline 189 participants Est. completion 2015-06-11 8 sites
    Other conditions: Meningococcal Disease
    View official trial listing →
  • Completed NCT NCT02446691

    Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

    Not yet reported GlaxoSmithKline 128 participants Est. completion 2017-12-28 6 sites Stand-alone
    Other conditions: Infections, Meningococcal
    View official trial listing →
  • Completed NCT NCT02451514

    A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)

    Not yet reported GlaxoSmithKline 129 participants Est. completion 2015-12-10 7 sites Stand-alone
    Other conditions: Meningococcal Disease, Infections, Meningococcal
    View official trial listing →
  • Completed NCT NCT03433482

    A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age

    Not yet reported GlaxoSmithKline 1707 participants Est. completion 2019-12-17 49 sites
    Other conditions: Meningitis, Meningococcal
    View official trial listing →
  • Completed NCT NCT03493919

    A Sourcing Study to Collect Human Blood Samples From Healthy Adults

    Not yet reported GlaxoSmithKline 1021 participants Est. completion 2022-05-27 6 sites Stand-alone
    Other conditions: Meningitis, Meningococcal
    View official trial listing →
  • Completed NCT NCT03652610

    A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

    Not yet reported GlaxoSmithKline 996 participants Est. completion 2019-06-11 30 sites
    Other conditions: Infections, Meningococcal
    View official trial listing →
  • Completed NCT NCT03929757

    A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants

    Not yet reported Janssen Vaccines & Prevention B.V. 108 participants Est. completion 2022-09-28 2 sites
    Other conditions: Ebola Virus Disease
    View official trial listing →
  • Completed NCT NCT04318548

    Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

    Not yet reported GlaxoSmithKline 945 participants Est. completion 2023-11-21 53 sites Stand-alone
    Other conditions: Infections, Meningococcal
    View official trial listing →
  • Completed NCT NCT04324606

    A Study of a Candidate COVID-19 Vaccine (COV001)

    Not yet reported, Not yet reported University of Oxford 1077 participants Est. completion 2025-02-05 6 sites Stand-alone
    Other conditions: Coronavirus
    View official trial listing →
  • Completed NCT NCT04400838

    Investigating a Vaccine Against COVID-19

    Not yet reported, Not yet reported University of Oxford 10811 participants Est. completion 2025-02-05 20 sites
    Other conditions: Coronavirus
    View official trial listing →
  • Completed NCT NCT04502693

    Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

    Not yet reported GlaxoSmithKline 3657 participants Est. completion 2022-09-13 112 sites Stand-alone
    Other conditions: Infections, Meningococcal
    View official trial listing →
  • Completed NCT NCT04707391

    Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

    Not yet reported GlaxoSmithKline 1250 participants Est. completion 2023-09-29 69 sites
    Other conditions: Meningitis, Meningococcal
    View official trial listing →
  • Completed NCT NCT04886154

    A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

    Not yet reported, Not yet reported GlaxoSmithKline 1440 participants Est. completion 2024-02-02 53 sites
    Other conditions: Infections, Meningococcal
    View official trial listing →
  • Completed NCT NCT05873751

    A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

    Pfizer 1307378 participants Est. completion 2024-03-31 1 site
    Other conditions: Gonorrhea, Chlamydia, Meningococcal Vaccines
    View official trial listing →
  • Completed NCT NCT05919472

    Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women

    Not yet reported Nicole Stoffel 180 participants Est. completion 2024-07-16 1 site Stand-alone
    Other conditions: Iron Deficiency Anemia
    View official trial listing →
  • Completed NCT NCT06116669

    Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women

    Not yet reported Swiss Federal Institute of Technology 215 participants Est. completion 2024-07-31 1 site Stand-alone
    Other conditions: Iron Deficiency Anemia
    View official trial listing →
  • Completed NCT NCT06213506

    A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

    Not yet reported GlaxoSmithKline 180 participants Est. completion 2026-08-06 1 site
    Other conditions: Salmonella Infections
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.